← Leaderboards
Tim H.-M. Huang
University Of Missouri-Columbia
$22,527,443
Attributed
$24,968,545
Total exposure
17
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$52,640,423 · 20
By mechanism
U54$34,384,276 · 6
R01$7,850,434 · 4
U01$4,547,902 · 3
R33$2,622,880 · 2
P30$2,326,896 · 1
P50$406,004 · 1
Top collaborators
- Victor Jin5 shared
- Nameer Kirma5 shared
- Qianben Wang5 shared
- Coral Lamartiniere4 shared
- Jose Russo4 shared
- David Scott Miller3 shared
Most similar at University Of Missouri-Columbia
Same institution · by research overlap
- Huidong Shi$4,464,396
- Charlotte L Phillips$2,622,805
- Kiruba Krishnaswamy$448,115
Others in their field
Top investigators on “Dna Methylation”
- Richard K. Wilson · Washington University$74,307,196
- Bing Ren · Ludwig Institute For Cancer Research$63,053,519
- Leonardo Trasande · New York University School Of Medicine$50,897,521
- Richard M Myers · Hudson-Alpha Institute For Biotechnology$47,754,231
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$46,590,951
- Joseph R Ecker · University Of California, San Diego$45,558,745
Research focus
Dna MethylationEpigenetic ProcessMalignant NeoplasmsPrimary NeoplasmBaseCancer PatientGenesSignal TransductionMethylationCpg IslandsCellsCancer CellResearch PersonnelMolecularGene ExpressionMediatingFutureProgramsChromatinGenetic TranscriptionPromotor (Genetics)PlayHypermethylationPattern
Grant awards (89)
The role of tumor-macrophage hybrid cells in prostate cancer metastasis$637,168
U01 · FY2025 · CA · contact PI
PAI-1-mediated early-onset endometrial cancer$402,201
R01 · FY2025 · CA
The role of tumor-macrophage hybrid cells in prostate cancer metastasis$637,168
U01 · FY2024 · CA · contact PI
PAI-1-mediated early-onset endometrial cancer$424,546
R01 · FY2024 · CA
PAI-1-mediated early-onset endometrial cancer$437,953
R01 · FY2023 · CA · contact PI
PAI-1-mediated early-onset endometrial cancer$437,949
R01 · FY2022 · CA · contact PI
Systems Analysis of Epigenomic Architecture in Cancer Progression$1,763,095
U54 · FY2021 · CA · contact PI
PAI-1-mediated early-onset endometrial cancer$446,169
R01 · FY2021 · CA · contact PI
Systems Analysis of Epigenomic Architecture in Cancer Progression$293,850
U54 · FY2021 · CA · contact PI
Systems Analysis of Epigenomic Architecture in Cancer Progression$1,735,899
U54 · FY2020 · CA · contact PI
Systems Analysis of Epigenomic Architecture in Cancer Progression$217,617
U54 · FY2020 · CA · contact PI
Systems Analysis of Epigenomic Architecture in Cancer Progression$1,729,895
U54 · FY2019 · CA · contact PI
Systems Analysis of Epigenomic Architecture in Cancer Progression$217,435
U54 · FY2019 · CA · contact PI
Systems Analysis of Epigenomic Architecture in Cancer Progression$2,104,443
U54 · FY2018 · CA · contact PI
Novel epigenetic paradigm in endometrial cancer recurrence$308,364
R01 · FY2018 · CA · contact PI
Systems Analysis of Epigenomic Architecture in Cancer Progression$273,248
U54 · FY2018 · CA · contact PI
Systems Analysis of Epigenomic Architecture in Cancer Progression$1,918,884
U54 · FY2017 · CA · contact PI
Novel epigenetic paradigm in endometrial cancer recurrence$308,364
R01 · FY2017 · CA · contact PI
Systems Analysis of Epigenomic Architecture in Cancer Progression$218,557
U54 · FY2017 · CA · contact PI
Cancer Therapy & Research Center at UTHSCSA$2,093,000
P30 · FY2016 · CA · contact PI
Novel epigenetic paradigm in endometrial cancer recurrence$308,364
R01 · FY2016 · CA · contact PI
Cancer Therapy & Research Center at UTHSCSA$121,141
P30 · FY2016 · CA · contact PI
Cancer Therapy & Research Center at UTHSCSA$112,755
P30 · FY2016 · CA · contact PI
Novel epigenetic paradigm in endometrial cancer recurrence$308,364
R01 · FY2015 · CA · contact PI
Interrogating Epigenetic Changes in Cancer Genomes$1,631,430
U54 · FY2014 · CA · contact PI
Interrogating Epigenetic Changes in Cancer Genomes$1,631,430
U54 · FY2014 · CA · contact PI
Novel epigenetic paradigm in endometrial cancer recurrence$308,364
R01 · FY2014 · CA · contact PI
Interrogating Epigenetic Changes in Cancer Genomes$1,841,029
U54 · FY2013 · CA · contact PI
Interrogating Epigenetic Changes in Cancer Genomes$1,436,990
U54 · FY2013 · CA · contact PI
Combinational Environmental Chemicals Altering Susceptibility for Mammary Cancer$411,383
U01 · FY2013 · ES
Epigenomics of Bisphenol A Exposure and Disease Risk$329,808
R01 · FY2013 · ES · contact PI
Interrogating Epigenetic Changes in Cancer Genomes$1,541,529
U54 · FY2012 · CA · contact PI
Interrogating Epigenetic Changes in Cancer Genomes$1,536,572
U54 · FY2012 · CA · contact PI
Combinational Environmental Chemicals Altering Susceptibility for Mammary Cancer$433,081
U01 · FY2012 · ES
Epigenomics of Bisphenol A Exposure and Disease Risk$338,108
R01 · FY2012 · ES · contact PI
Interrogating Epigenetic Changes in Cancer Genomes$1,728,938
U54 · FY2011 · CA · contact PI
Interrogating Epigenetic Changes in Cancer Genomes$1,613,665
U54 · FY2011 · CA · contact PI
Combinational Environmental Chemicals Altering Susceptibility for Mammary Cancer$461,572
U01 · FY2011 · ES
Epigenomics of Bisphenol A Exposure and Disease Risk$315,954
R01 · FY2011 · ES · contact PI
CpG Island Methylator Phenotypes in Breast Cancer$258,886
R01 · FY2011 · CA · contact PI
Methylation Markers for Prognosis in Endometriod Endometrial Cancers$144,838
P50 · FY2011 · CA · contact PI
Epigenomics of Bisphenol A Exposure and Disease Risk$33,038
R01 · FY2011 · ES · contact PI
CpG Island Methylator Phenotypes in Breast Cancer$2,642
R01 · FY2011 · CA · contact PI
Interrogating Epigenetic Changes in Cancer Genomes$1,596,781
U54 · FY2010 · CA · contact PI
Combinational Environmental Chemicals Altering Susceptibility for Mammary Cancer$439,500
U01 · FY2010 · ES
Epigenomics of Bisphenol A Exposure and Disease Risk$371,250
R01 · FY2010 · ES · contact PI
Environmental Epigenetics and Stem/Progenitor Cell Injury$311,424
U01 · FY2010 · ES · contact PI
CpG Island Methylator Phenotypes in Breast Cancer$272,340
R01 · FY2010 · CA · contact PI
Methylation Markers for Prognosis in Endometriod Endometrial Cancers$152,900
P50 · FY2010 · CA · contact PI
Interrogating Epigenetic Changes in Cancer Genomes$88,000
U54 · FY2010 · CA · contact PI
Environmental Epigenetics and Stem/Progenitor Cell Injury$65,207
U01 · FY2010 · ES · contact PI
Environmental Epigenetics and Stem/Progenitor Cell Injury$1,000
U01 · FY2010 · ES · contact PI
Interrogating Epigenetic Changes in Cancer Genomes$723,898
U54 · FY2009 · CA · contact PI
Environmental Epigenetics and Stem/Progenitor Cell Injury$378,969
U01 · FY2009 · ES · contact PI
Epigenomics of Bisphenol A Exposure and Disease Risk$375,000
R01 · FY2009 · ES · contact PI
CpG Island Methylator Phenotypes in Breast Cancer$272,340
R01 · FY2009 · CA · contact PI
Methylation Markers for Prognosis in Endometriod Endometrial Cancers$108,266
P50 · FY2009 · CA · contact PI
Interrogating Epigenetic Changes in Cancer Genomes$1,448,118
U54 · FY2008 · CA · contact PI
Environmental Epigenetics and Stem/Progenitor Cell Injury$367,928
U01 · FY2008 · ES · contact PI
CpG Island Methylator Phenotypes in Breast Cancer$272,340
R01 · FY2008 · CA · contact PI
Dissecting Hierarchies of Epigenetic Control in Gene Silencing$266,215
U54 · FY2008 · CA · contact PI
Environmental Epigenetics and Stem/Progenitor Cell Injury$36,000
U01 · FY2008 · ES · contact PI
Interrogating Epigenetic Changes in Cancer Genomes$1,438,644
U54 · FY2007 · CA · contact PI
Environmental Epigenetics and Stem/Progenitor Cell Injury$367,502
U01 · FY2007 · ES · contact PI
Dissecting Hierarchies of Epigenetic Control in Gene Silencing$292,548
U54 · FY2007 · CA · contact PI
CpG Island Methylator Phenotypes in Breast Cancer$272,340
R01 · FY2007 · CA · contact PI
Interrogating Epigenetic Changes in Cancer Genomes$150,000
U54 · FY2007 · CA · contact PI
Interrogating Epigenetic Changes in Cancer Genomes$1,443,474
U54 · FY2006 · CA · contact PI
Dissecting Hierarchies of Epigenetic Control in Gene Silencing$187,429
U54 · FY2006 · CA · contact PI
Interrogating Epigenetic Changes in Cancer Genomes$7,807
U54 · FY2006 · CA · contact PI
Interrogating Epigenetic Changes in Cancer Genomes$1,440,303
U54 · FY2005 · CA
Novel Tool for Analysis of Promoter Hypermethylation$378,836
R33 · FY2005 · CA
DNA Hypermethylation in Breast Cancer$262,550
R01 · FY2005 · CA
Dissecting Hierarchies of Epigenetic Control in Gene Silencing$182,823
U54 · FY2005 · CA
Epigenetic Biomarkers for Ovarian Cancer Progression$119,439
R21 · FY2005 · CA
Interrogating Epigenetic Changes in Cancer Genomes$1,421,811
U54 · FY2004 · CA
Novel Tool for Analysis of Promoter Hypermethylation$369,086
R33 · FY2004 · CA
DNA Hypermethylation in Breast Cancer$262,550
R01 · FY2004 · CA
Dissecting Hierarchies of Epigenetic Control in Gene Silencing$178,355
U54 · FY2004 · CA
Epigenetic Biomarkers for Ovarian Cancer Progression$129,828
R21 · FY2004 · CA
Administration$83,564
U54 · FY2004 · CA
Novel Tool for Analysis of Promoter Hypermethylation$539,048
R33 · FY2003 · CA
DNA Hypermethylation in Breast Cancer$262,550
R01 · FY2003 · CA
HIGH THROUGHPUT METHYLATION ANALYSIS IN CANCER$492,211
R33 · FY2002 · CA
DNA Hypermethylation in Breast Cancer$258,100
R01 · FY2002 · CA
Novel Tool for Analysis of Promoter Hypermethylation$145,000
R21 · FY2002 · CA
HIGH THROUGHPUT METHYLATION ANALYSIS IN CANCER$343,855
R33 · FY2001 · CA
HIGH THROUGHPUT METHYLATION ANALYSIS IN CANCER$499,844
R33 · FY2000 · CA
DNA HYPERMETHYLATION IN BREAST CANCER$107,764
R29 · FY2000 · CA